(Q40708026)

22 September 2017

title

Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors (English)

1 reference

22 September 2017

Dorsey JF

1

1 reference

22 September 2017

Cunnick JM

2

1 reference

22 September 2017

Lanehart R

3

1 reference

22 September 2017

Huang M

4

1 reference

22 September 2017

Kraker AJ

5

1 reference

22 September 2017

Bhalla KN

6

1 reference

22 September 2017

Jove R

7

1 reference

22 September 2017

Wu J

8

1 reference

22 September 2017

publication date

1 September 2002

1 reference

22 September 2017

1 reference

22 September 2017

volume

16

1 reference

22 September 2017

issue

9

1 reference

22 September 2017

page(s)

1589-1595

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402678

22 September 2017

exact match

0 references

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Imatinib mesylate--a new oral targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Kinetic properties of the C-terminal Src kinase, p50csk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Another version of the human insulin receptor kinase domain: expression, purification, and characterization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402678

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402678

1 reference

Dimensions Publication ID

22 September 2017

1027872010

0 references

1 reference